英雄联盟赛事统计新版
- ID:OGAMSC1908154
- Published: August-2021
- Pages:130
- OGAnalysis
Global Hemophilia Market Size, Share, Outlook and Growth Opportunities to 2026: By Function Type (Hemophilia A, Hemophilia B, Hemophilia C, and Others), By Treatment (Prophylaxis, on-demand), By Therapy (Replacement therapy, Gene therapy, and ITI therapy) and By Region
Key Highlights
- Global Hemophilia market registered at a CAGR of 5.11% during the forecast period 2020 to 2026.
- Based on Types, Hemophilia A is the leading type in the global haemophilia market. Hemophilia B is fastest growing segment.
- Based on treatment methods, global hemophilia market is segmented into Prophylaxis, and on-demand.
- Replacement therapy, Gene therapy, and ITI therapy are the three therapies categorized in global haemophilia market.
- North America region leads among the global haemophilia market.
Hemophilia:
Hemophilia is rare health condition where the blood is unable to clot after cuts, mutations and others. Increasing necessity of public suffering from hemophilia on the targeted audience to implement prophylaxis treatment and other government initiatives are acting as hemophilia market drivers.
Some of the government agencies and authorities such as CDC’s National Center on Birth Defects and Developmental Disabilities (NCBDDD undertakes many initiative programs to create public awareness regarding blood disorders and associated complications. For instance, as of on July 2020 the International Society on Thrombosis and Haemostasis (ISTH) launched global education initiative in gene therapy for hemophilia.
High cost of hemophilia medication is the major restrain that is influencing the growth of hemophilia market size. The factors such as R&D costs, high investments, production and distribution of drugs are the main reasons that are leading towards the high cost of hemophilia products and services. In addition, the high cost of hemophilia products are unaffordable by low and middle income class families across the emerging countries until and unless government initiatives and subsidiaries are implemented.
The key players in the hemophilia market are launching the innovative products and other drugs used hemophilia medication. Introduction of new products and services are the key strategies to expand their business operation and market presence. For instance, on September 2020 Sigilon Therapeutics received Orphan Drug Designation for SIG-001, an investigation therapy for hemophilia A.
Based on type, hemophilia is categorized into three types including hemophilia A, hemophilia B, and hemophilia C. among these, Hemophilia A is a common blood disorder and the incidence of this disease is more in both the emerged and emerging nations.
According to National Hemophilia Foundation, Hemophilia A occurs in 1 in 5,000 live male births. The prevalence of hemophilia A is four times more compared to hemophilia B. Globally, incidence of hemophilia is estimated to be more than 400, 000 people. Among, these third fourth of people with hemophilia world-wide receive inadequate treatment and in some areas, they don’t even have access to hemophilia treatment.
There are key therapies that are available in the market for the treatment of hemophilia such as replacement therapy, gene therapy, and immune tolerance induction therapy. Among these genetherapy is wide used for the treatment of hemophilia due to its identification of defective DNA bases and reinstating with functional ones. Further, the clinical trials are taking place for the treatment of hemophilia, and market share of genetherapy is estimated to accelerate in upcoming years.
Prevalence of hemophilia is high in North America region coupled with rising incidence towards the prophylaxis treatment. In the United States, the prevalence of hemophilia is estimated to be more than 20,000 people.
Global Hemophilia Market Insights
The 2020 series of global market size, share, outlook, trends and growth prospects is a comprehensive analysis on global Hemophilia market conditions. Major trends shaping the near and long term future of the industry, opportunities, drivers and restraints of Hemophilia market, detailed porter’s five forces analysis and competitive insights are included in the research report.
Global Hemophilia Market Share by Type
The report presents the detailed annual outlook of each type of the Hemophilia market to 2026. Hemophilia A, Hemophilia B, Hemophilia C, and Others are four types included in the Hemophilia market report. Of these types, Hemophilia A occupies major share in the global industry.
Global Hemophilia Market Share by Treatment
The report present the detailed annual outlook of Hemophilia market based on each treatment to 2026. Prophylaxis and on-demand are the two therapies in global hemophilia market report.
Global Hemophilia Market Size by Therapy
Amidst increasing emphasis on new therapies and stagnant growth of conventional large therapies, the report presents in-depth insights into each of the leading Hemophilia treatment verticals along with annual forecasts to 2026. Various therapies that are studied in the report include Replacement therapy, Gene therapy, and ITI therapy.
Global Hemophilia Market Revenue by Region
The current Hemophilia market size in terms of revenue across 5 regions including North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa are studied in the report. In addition, historic data from 2017 and annual forecasts to 2026 are also included in the research report. Globally, North America is the major revenue contributor to the global market.
Global Hemophilia Market Analysis by Company
Top 10 leading companies in global Hemophilia market are analyzed in the report along with their business overview, operations, geographical locations, financial analysis, SWOT profile and Hemophilia products & services.
Global Hemophilia Market News and Recent Developments
Latest news and industry developments in terms of Hemophilia capacity expansions, acquisitions, organic & inorganic growth strategies, joint ventures and collaborations, product launches, market expansions etc are included in the report.
Scope
Long term perspective on the Hemophilia industry: 2020 (base year), 2020- 2026 (forecast period)
Hemophilia Market- Forecasts by Segments- Type, Therapy and Treatment by geography.
- The research work categorizes the global Hemophilia market based on type into 4 categories including Hemophilia A, Hemophilia B, Hemophilia C, and Others.
- The report segmented the global hemophilia market based on treatment into 2 types including Prophylaxis, and on-demand.
- The report categorizes the market based on therapies into 3 categories such as Replacement therapy, Gene therapy, and ITI therapy.
- Hemophilia market across countries in 5 regions including North America, Europe, Asia-Pacific, South & Central America and Middle East & Africa are covered.
Hemophilia Market- Strategic Analysis Review
- Key strategies opted by leading players
- Short to Long Term Industry Trends
- Porter’s Five Forces Analysis
- Supply side and Demand Side Drivers and Challenges
Hemophilia Market- Growth Opportunities
- Potential New Business Opportunities
- Key Areas of Focus in forecast period
Hemophilia Market- Competitive Scenario
- 10 companies are analysed in the report including Novo Nordisk, Biogen., Chugai Pharmaceutical, Bayer Healthcare, Pfizer., Shire Plc, Baxalta (Baxter Healthcare), CSL Behring., Octapharma., and Sanofi SA.
- Company Peer-to-Peer Comparison
- Company Profile and SWOT Analysis
- Financial Analysis
Table of Contents
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Introduction to Global Hemophilia Market
2.1 Global Hemophilia Market Snapshot, 2020
2.2 Hemophilia Industry Overview
2.3 Research Perspective
3. Global Hemophilia Market- Strategic Analysis
3.1 Short Term and Long Term Industry Trends Affecting Global Hemophilia Market
3.2 Leading Hemophilia Types Targeted by Global Manufacturers
3.3 Key Consumption Patterns of Hemophilia
3.4 Potential Markets Vital for business Expansion
3.5 Five Forces Analysis
3.6 Drivers and Restraints
4. Global Hemophilia Market Outlook and Growth Opportunities by Type
4.1 Hemophilia A, Market Outlook, 2020- 2026
4.2 Hemophilia B, Market Outlook, 2020- 2026
4.3 Hemophilia C, Market Outlook, 2020- 2026
4.4 Hemophilia by Other Types, Market Outlook, 2020- 2026
5. Global Hemophilia Market Outlook and Growth Opportunities by Treatment
5.1 Hemophilia Demand in Prophylaxis Treatment, Market Outlook, 2020- 2026
5.2 Hemophilia Demand in on-demand Treatment, Market Outlook, 2020- 2026
6. Global Hemophilia Market Outlook and Growth Opportunities by Therapy
6.1 Hemophilia Demand in Replacement Therapy, Market Outlook, 2020- 2026
6.2 Hemophilia Demand in Gene Therapy, Market Outlook, 2020- 2026
6.3 Hemophilia Demand in ITI Therapy, Market Outlook, 2020- 2026
7. Asia Pacific Hemophilia Market Outlook and Growth Opportunities
7.1 Key Findings, 2020
7.2 Asia Pacific Hemophilia Market Outlook by Type, 2020- 2026
7.3 Asia Pacific Hemophilia Market Outlook by Treatment, 2020- 2026
7.4 Asia Pacific Hemophilia Market Outlook by Therapy, 2020- 2026
7.5 Asia Pacific Hemophilia Market Outlook by Country, 2020- 2026
8. Europe Hemophilia Market Outlook and Growth Opportunities
8.1 Key Findings, 2020
8.2 Europe Hemophilia Market Outlook by Type, 2020- 2026
8.3 Europe Hemophilia Market Outlook by Treatment, 2020- 2026
8.4 Europe Hemophilia Market Outlook by Therapy, 2020- 2026
8.5 Europe Hemophilia Market Outlook by Country, 2020- 2026
9. North America Hemophilia Market Outlook and Growth Opportunities
9.1 Key Findings, 2020
9.2 North America Hemophilia Market Outlook by Type, 2020- 2026
9.3 North America Hemophilia Market Outlook by Treatment, 2020- 2026
9.4 North America Hemophilia Market Outlook by Therapy, 2020- 2026
9.5 North America Hemophilia Market Outlook by Country, 2020- 2026
10. South & Central America Hemophilia Market Outlook and Growth Opportunities
10.1 Key Findings, 2020
10.2 South & Central America Hemophilia Market Outlook by Type, 2020- 2026
10.3 South & Central America Hemophilia Market Outlook by Treatment, 2020- 2026
10.4 South & Central America Hemophilia Market Outlook by Therapy, 2020- 2026
10.5 South & Central America Hemophilia Market Outlook by Country, 2020- 2026
11. Middle East & Africa Hemophilia Market Outlook and Growth Opportunities
11.1 Key Findings, 2020
11.2 Middle East & Africa Hemophilia Market Outlook by Type, 2020- 2026
11.3 Middle East & Africa Hemophilia Market Outlook by Treatment, 2020- 2026
11.4 Middle East & Africa Hemophilia Market Outlook by Therapy, 2020- 2026
11.5 Middle East & Africa Hemophilia Market Outlook by Country, 2020- 2026
12. Competitive Landscape
12.1 Leading Players (Company Profile, SWOT Analysis, Hemophilia Products, Financial Analysis)
12.1.1 Novo Nordisk,
12.1.2 Biogen.
12.1.3 Chugai Pharmaceutical
12.1.4 Bayer Healthcare
12.1.5 Pfizer.
12.1.6 Shire Plc
12.1.7 Baxalta (Baxter Healthcare)
12.1.8 CSL Behring.
12.1.9 Octapharma.
12.1.10 Sanofi SA.
12.2 Company Benchmarking
12.3 Financial Analysis
13. Recent News and Deals Landscape
13.1 Mergers and Acquisitions
13.2 New Product Launches
13.3 Asset Transactions
13.4 Financial Announcements
14. Appendix
14.1 OGAnalysis Expertise
14.2 Sources and Research Methodology
14.3 Contact Information
| Type | Delivery Format | Details |
|---|---|---|
| Hard Copy | A printed copy of the report will be shipped to you. | |
| CD-ROM | The report will be shipped to you in CD ROM format. | |
| SINGLE USER Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows one specific user access to the product. |
| SITE LICENSE Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows all users within a given geographical location of your organization access to the product. |
| ENTERPRISEWIDE Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows all employees within your organization in different geographic locations access to the product. |
| 1 - 5 USERS Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows up to five users have access to the product. |
| 1 – 10 USERS Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows up to ten users have access to the product. |
| 1 – 15 USERS Electronic (PDF) | The report will be delivered to your email address in PDF format. | The license allows up to fifteen users have access to the product. |
| 1 - 5 USERS Online Access (For Databases) | Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. | The license allows up to five users have access to the product. |
| 1 - 10 USERS Online Access(For Databases) | Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. | The license allows up to ten users have access to the product. |
| 1 - 15 USERS Online Access(For Databases) | Database is accessed online through a secure website. You will receive a username and password via email to access to the online directory. | The license allows up to fifteen users have access to the product. |
| 1 - 5 USERS Electronic (Excel) | The Excel spreadsheet will be emailed to you. | The license allows up to five users have access to the product. |